Published in J Cardiovasc Pharmacol on June 01, 2008
Arterial stiffness and cardiovascular therapy. Biomed Res Int (2014) 1.03
Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series). Pulm Circ (2014) 0.87
Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections. Pulse (Basel) (2013) 0.81
Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for stroke. Stroke Vasc Neurol (2017) 0.75
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol (2011) 2.85
A gentle ethical defence of homeopathy. J Bioeth Inq (2014) 2.13
Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv (2010) 2.04
"They all work...when you stick to them": a qualitative investigation of dieting, weight loss, and physical exercise, in obese individuals. Nutr J (2008) 1.99
Endogenous estrogens influence endothelial function in young men. Circ Res (2003) 1.98
Being 'fat' in today's world: a qualitative study of the lived experiences of people with obesity in Australia. Health Expect (2008) 1.84
Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol (2011) 1.69
Transient left ventricular dysfunction under severe stress: brain-heart relationship revisited. Am J Med (2006) 1.59
Periprocedural myocardial infarction in a randomized trial of everolimus-eluting and Paclitaxel-eluting coronary stents: frequency and impact on mortality according to historic versus universal definitions. Circ Cardiovasc Interv (2012) 1.52
Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer. Clin Endocrinol (Oxf) (2002) 1.40
Laser acupuncture does not improve menopausal symptoms. Menopause (2010) 1.40
Impaired acetylcholine-induced release of nitric oxide in the aorta of male aromatase-knockout mice: regulation of nitric oxide production by endogenous sex hormones in males. Circ Res (2003) 1.28
How do obese individuals perceive and respond to the different types of obesity stigma that they encounter in their daily lives? A qualitative study. Soc Sci Med (2011) 1.18
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv (2013) 1.14
Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology (2002) 1.12
The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. EuroIntervention (2015) 1.12
Understanding the reliability of diagnostic variables in a Chinese Medicine examination. J Altern Complement Med (2009) 1.12
Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol (2010) 1.06
Improving communication when seeking informed consent: a randomised controlled study of a computer-based method for providing information to prospective clinical trial participants. Med J Aust (2010) 1.06
An investigation into the reliability of Chinese medicine diagnosis according to Eight Guiding Principles and Zang-Fu Theory in Australians with hypercholesterolemia. J Altern Complement Med (2009) 1.05
Location of focal vasospasm provoked by ergonovine maleate within coronary arteries in patients with vasospastic angina pectoris. Am J Cardiol (2006) 1.04
"I don't eat a hamburger and large chips every day!" A qualitative study of the impact of public health messages about obesity on obese adults. BMC Public Health (2010) 1.03
Do health beliefs and behaviors differ according to severity of obesity? A qualitative study of Australian adults. Int J Environ Res Public Health (2010) 1.01
Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J (2006) 0.98
Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab (2004) 0.96
'I'm searching for solutions': why are obese individuals turning to the Internet for help and support with 'being fat'? Health Expect (2010) 0.96
SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J (2009) 0.95
A new sol-gel process for producing Na(2)O-containing bioactive glass ceramics. Acta Biomater (2010) 0.94
Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol (2011) 0.93
Effects of a Chinese herbal preparation on vascular cells in culture: mechanisms of cardiovascular protection. Clin Exp Pharmacol Physiol (2005) 0.93
A qualitative investigation of obese men's experiences with their weight. Am J Health Behav (2011) 0.93
Pet ownership and cardiovascular risk reduction: supporting evidence, conflicting data and underlying mechanisms. Clin Exp Pharmacol Physiol (2011) 0.92
In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. EuroIntervention (2010) 0.91
Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab (2002) 0.91
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention (2012) 0.90
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv (2012) 0.90
Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase-knockout mouse. Circulation (2004) 0.88
Promises and ethical pitfalls of surgical innovation: the case of bariatric surgery. Obes Surg (2013) 0.87
Cellular mechanisms underlying the cardiovascular actions of oestrogens. Clin Sci (Lond) (2006) 0.87
Investigating the reliability of Japanese toyohari meridian therapy diagnosis. J Altern Complement Med (2009) 0.86
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent. Coron Artery Dis (2010) 0.86
A pharmaceutical preparation of Salvia miltiorrhiza protects cardiac myocytes from tumor necrosis factor-induced apoptosis and reduces angiotensin II-stimulated collagen synthesis in fibroblasts. Phytomedicine (2008) 0.85
A chinese herbal preparation containing radix salviae miltiorrhizae, radix notoginseng and borneolum syntheticum reduces circulating adhesion molecules. Evid Based Complement Alternat Med (2011) 0.85
Impact of routine angiographic follow-up after percutaneous coronary intervention with drug-eluting stents in the SPIRIT III randomized trial at three years. Am J Cardiol (2012) 0.84
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention (2011) 0.83
Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. J Interv Cardiol (2011) 0.83
Effects of 17beta-estradiol on growth and apoptosis in human vascular endothelial cells: influence of mechanical strain and tumor necrosis factor-alpha. Steroids (2006) 0.82
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study. EuroIntervention (2011) 0.81
Comparison of everolimus- versus paclitaxel-eluting stents implanted in patients with diabetes mellitus as evaluated by three-dimensional intravascular ultrasound analysis. Am J Cardiol (2010) 0.81
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. Int J Cardiovasc Imaging (2010) 0.81
A preparation of herbal medicine Salvia miltiorrhiza reduces expression of intercellular adhesion molecule-1 and development of atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol (2008) 0.81
Effect of intracoronary estradiol on postischemic microvascular damage in a porcine model: a myocardial contrast echocardiographic study. Angiology (2003) 0.80
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc Interv (2011) 0.80
SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol (2010) 0.80
High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells. Am J Physiol Endocrinol Metab (2002) 0.80
Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. Am Heart J (2009) 0.80
The isoflavone metabolite cis-tetrahydrodaidzein inhibits ERK-1 activation and proliferation in human vascular smooth muscle cells. J Cardiovasc Pharmacol (2004) 0.79
Late-acquired incomplete stent apposition: morphologic characterization. Cardiovasc Revasc Med (2009) 0.79
An expanding vista: bioethics from public health, indigenous and feminist perspectives. Med J Aust (2005) 0.79
Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. Endocrinology (2005) 0.79
The Endocrine Society Ethics Advisory Committee: ethical aspects of conflicts of interests, October 2003. Endocrinology (2004) 0.78
Urotensin II in chronic liver disease: in vivo effect on vascular tone. Scand J Gastroenterol (2008) 0.78
Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care (2003) 0.78
Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women. Endocr Metab Immune Disord Drug Targets (2009) 0.78
Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial. EuroIntervention (2012) 0.78
Three-year results of safety and efficacy of the everolimus-eluting coronary stent in women (from the SPIRIT III randomized clinical trial). Am J Cardiol (2011) 0.78
Hormone therapy impairs endothelial function in postmenopausal women with type 2 diabetes mellitus treated with rosiglitazone. J Clin Endocrinol Metab (2004) 0.77
Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter Cardiovasc Interv (2010) 0.77
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention (2010) 0.77
Dehydroepiandrosterone sulfate induces acute vasodilation of porcine coronary arteries in vitro and in vivo. J Cardiovasc Pharmacol (2005) 0.77
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. EuroIntervention (2010) 0.77
Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study. Catheter Cardiovasc Interv (2013) 0.77
Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials. EuroIntervention (2012) 0.77
Progesterone does not influence vascular function in postmenopausal women. J Hypertens (2003) 0.77
SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes. EuroIntervention (2012) 0.77
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Catheter Cardiovasc Interv (2009) 0.76
The anti-atherogenic effects of thiazolidinediones. Curr Diabetes Rev (2007) 0.76
Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv (2002) 0.76
Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. EuroIntervention (2010) 0.76
Taxol-based eluting stents from theory to human validation: clinical and intravascular ultrasound observations. J Invasive Cardiol (2003) 0.76